PSNL Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of -152.04% compared to Personalis's net margin of --. Personalis's return on equity of -67.2% beat Perspective Therapeutics's return on equity of --.

Personalis has a consensus price target of $7.58, signalling upside risk potential of 21.15%. On the other hand Perspective Therapeutics has an analysts' consensus of $16.15 which suggests that it could grow by 390.88%. Given that Perspective Therapeutics has higher upside potential than Personalis, analysts believe Perspective Therapeutics is more attractive than Personalis.

Personalis has a beta of 1.877, which suggesting that the stock is 87.655% more volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.129, suggesting its more volatile than the S&P 500 by 12.894%.

Personalis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Personalis pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Personalis quarterly revenues are $25.7M, which are larger than Perspective Therapeutics quarterly revenues of --. Personalis's net income of -$39.1M is lower than Perspective Therapeutics's net income of -$15.1M. Notably, Personalis's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Personalis is 3.82x versus 17.77x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

CareDx has a net margin of -152.04% compared to Personalis's net margin of -8.94%. Personalis's return on equity of -67.2% beat CareDx's return on equity of -49.52%.

Personalis has a consensus price target of $7.58, signalling upside risk potential of 21.15%. On the other hand CareDx has an analysts' consensus of $35.20 which suggests that it could grow by 61.69%. Given that CareDx has higher upside potential than Personalis, analysts believe CareDx is more attractive than Personalis.

Personalis has a beta of 1.877, which suggesting that the stock is 87.655% more volatile than S&P 500. In comparison CareDx has a beta of 1.840, suggesting its more volatile than the S&P 500 by 84.01%.

Personalis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CareDx offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Personalis pays -- of its earnings as a dividend. CareDx pays out -- of its earnings as a dividend.

Personalis quarterly revenues are $25.7M, which are smaller than CareDx quarterly revenues of $82.9M. Personalis's net income of -$39.1M is lower than CareDx's net income of -$7.4M. Notably, Personalis's price-to-earnings ratio is -- while CareDx's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Personalis is 3.82x versus 3.60x for CareDx. Usually stocks with elevated PS ratios are considered overvalued.

Electromed has a net margin of -152.04% compared to Personalis's net margin of 10.05%. Personalis's return on equity of -67.2% beat Electromed's return on equity of 15.62%.

Personalis has a consensus price target of $7.58, signalling upside risk potential of 21.15%. On the other hand Electromed has an analysts' consensus of -- which suggests that it could grow by 10.74%. Given that Personalis has higher upside potential than Electromed, analysts believe Personalis is more attractive than Electromed.

Personalis has a beta of 1.877, which suggesting that the stock is 87.655% more volatile than S&P 500. In comparison Electromed has a beta of 0.285, suggesting its less volatile than the S&P 500 by 71.506%.

Personalis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Personalis pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Personalis quarterly revenues are $25.7M, which are larger than Electromed quarterly revenues of $14.7M. Personalis's net income of -$39.1M is lower than Electromed's net income of $1.5M. Notably, Personalis's price-to-earnings ratio is -- while Electromed's PE ratio is 41.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Personalis is 3.82x versus 4.66x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -152.04% compared to Personalis's net margin of -17.98%. Personalis's return on equity of -67.2% beat Xtant Medical Holdings's return on equity of -35.98%.

Personalis has a consensus price target of $7.58, signalling upside risk potential of 21.15%. On the other hand Xtant Medical Holdings has an analysts' consensus of -- which suggests that it could grow by 418.19%. Given that Xtant Medical Holdings has higher upside potential than Personalis, analysts believe Xtant Medical Holdings is more attractive than Personalis.

Personalis has a beta of 1.877, which suggesting that the stock is 87.655% more volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.342%.

Personalis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Personalis pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Personalis quarterly revenues are $25.7M, which are smaller than Xtant Medical Holdings quarterly revenues of $27.9M. Personalis's net income of -$39.1M is lower than Xtant Medical Holdings's net income of -$5M. Notably, Personalis's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Personalis is 3.82x versus 0.51x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.